These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25423119)

  • 1. Effectiveness of protocol guided heparin anticoagulation in patients with the TandemHeart percutaneous ventricular assist device.
    Lee Y; Weeks PA
    ASAIO J; 2015; 61(2):207-8. PubMed ID: 25423119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing an Anti-Xa-Based Anticoagulation Protocol for Patients with Percutaneous Ventricular Assist Devices.
    Sieg A; Mardis BA; Mardis CR; Huber MR; New JP; Meadows HB; Cook JL; Toole JM; Uber WE
    ASAIO J; 2015; 61(5):502-8. PubMed ID: 26273933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulation Management for Impella Percutaneous Ventricular Assist Devices: An Analysis of a Single-Center Experience.
    Wood E; Hayes C; Hart A
    Ann Pharmacother; 2020 Nov; 54(11):1073-1082. PubMed ID: 32410456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective anticoagulation for a percutaneous ventricular assist device using a heparin-based purge solution.
    Jennings DL; Nemerovski CW; Kalus JS
    Ann Pharmacother; 2013 Oct; 47(10):1364-7. PubMed ID: 24259702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
    Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
    JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of a Percutaneously Inserted Ventricular Support Device Purge Solution Heparin 25 U/mL.
    Jiang C; Stuart M; Makowski C; Jennings DL; To L
    Ann Pharmacother; 2021 Feb; 55(2):174-180. PubMed ID: 32741200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic Considerations in the Management of Patients Receiving Left Ventricular Percutaneous Mechanical Circulatory Support.
    Allender JE; Reed BN; Foster JL; Moretz JD; Oliphant CS; Jennings DL; DiDomenico RJ; Coons JC
    Pharmacotherapy; 2017 Oct; 37(10):1272-1283. PubMed ID: 28741848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact and Statistical Analysis of a Multifaceted Anticoagulation Strategy in Children Supported on ECMO: Performance and Pitfalls.
    Kessel AD; Kline M; Zinger M; McLaughlin D; Silver P; Sweberg TM
    J Intensive Care Med; 2017 Jan; 32(1):59-67. PubMed ID: 26319579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a percutaneous left ventricular assist device for high-risk cardiac interventions and cardiogenic shock.
    Thomas JL; Al-Ameri H; Economides C; Shareghi S; Abad DG; Mayeda G; Burstein S; Shavelle DM
    J Invasive Cardiol; 2010 Aug; 22(8):360-4. PubMed ID: 20679671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a Nurse-Driven Heparin Monitoring Protocol for Ventricular Assist Devices.
    Gannon M; Simone PB
    AACN Adv Crit Care; 2021 Jun; 32(2):146-151. PubMed ID: 34161969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock.
    Burkhoff D; Cohen H; Brunckhorst C; O'Neill WW;
    Am Heart J; 2006 Sep; 152(3):469.e1-8. PubMed ID: 16923414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
    Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
    Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unfractionated Heparin Protocol During Percutaneous Left Ventricular Mechanical Circulatory (Impella) Support.
    Lee MC; Peters C; Rai N; Safani M; Thomas GS
    J Cardiovasc Pharmacol Ther; 2019 May; 24(3):251-253. PubMed ID: 30572718
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical experience and patient outcomes associated with the TandemHeart percutaneous transseptal assist device among a heterogeneous patient population.
    Tempelhof MW; Klein L; Cotts WG; Benzuly KH; Davidson CJ; Meyers SN; McCarthy PM; Malaisrie CS; McGee EC; Beohar N
    ASAIO J; 2011; 57(4):254-61. PubMed ID: 21546824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous left ventricular assist devices for treatment of patients with cardiogenic shock.
    Windecker S
    Curr Opin Crit Care; 2007 Oct; 13(5):521-7. PubMed ID: 17762230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial experience with the TandemHeart circulatory support system in children.
    Ricci M; Gaughan CB; Rossi M; Andreopoulos FM; Novello C; Salerno TA; Rosenkranz ER; Panos AL
    ASAIO J; 2008; 54(5):542-5. PubMed ID: 18812750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis.
    Elliott CG; Hiltunen SJ; Suchyta M; Hull RD; Raskob GE; Pineo GF; Jensen RL; Yeates S; Kitterman N
    Arch Intern Med; 1994 May; 154(9):999-1004. PubMed ID: 8179457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of unfractionated heparin using activated partial thromboplastin time: an assessment of the current nomogram and analysis according to age.
    Kim JS; Lee HJ; Sung JD; Kim HJ; Lee SY; Kim JS
    Clin Appl Thromb Hemost; 2014 Oct; 20(7):723-8. PubMed ID: 23615295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.